MRVI Q4 2024 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M-23.9% YoY

Gross Profit

$19M33.6% margin

Operating Income

-$38M-67.6% margin

Net Income

-$26M-46.4% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-13.5%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$20M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$431M

Stockholders' Equity

$325M

Cash & Equivalents

$322M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$74M	-23.9%
Gross Profit	$19M	$39M	-51.4%
Operating Income	-$38M	-$7M	-433.3%
Net Income	-$26M	-$106M	+75.3%

Revenue Segments

Nucleic Acid Production Segment

$100M77%

Biologics Safety Testing Segment

$29M23%

Geographic Segments

North America

$59M45%

Asia Pacific

$45M35%

EMEA

$25M19%

Latin And Central America

$230,0000%